Investigation of nonconformance and recurrence-prevention measures for STACY renewal and modification work
First written in FY2023-Q1. 1 of 4 entries say "Restated". Latest entry: FY2023.
No other company in this theme has enough history to compare yet.
- FY2023AchievedAnnual report
「At the company, nonconformance occurred at its Amagasaki Plant in connection with the manufacture of equipment for the STACY facility of the Nuclear Science Research Institute, Japan Atomic Energy Agency, a national research and development agency. The company established an investigation committee including independent experts and conducted an investigation. Based on the investigation results, the company will work to ensure the implementation of measures to prevent recurrence.」
The company disclosed that an investigation committee had investigated the nonconformance in the STACY renewal and modification work, and that it had moved on to thoroughly implementing measures to prevent recurrence based on the investigation results. - FY2023-Q3Continued investigation and recording of special investigation expenses, among other itemsAnnual report
「The company established an investigation committee including independent experts and is currently conducting an investigation to clarify the facts surrounding the nonconformance, identify its causes and make recommendations on measures to prevent recurrence. Extraordinary losses: Special investigation expenses 95; losses related to nonconforming products 77」
The investigation by a committee including independent experts into the facts and causes of the nonconformance and measures to prevent recurrence remains ongoing, and the company recorded ¥95 million in special investigation expenses and ¥77 million in losses related to nonconforming products. - FY2023-Q2RestatedAnnual report
「The company established an investigation committee including independent experts and is currently conducting an investigation to clarify the facts surrounding the nonconformance, identify its causes and make recommendations on measures to prevent recurrence. Special investigation expenses 82」
The investigation by a committee including independent experts into the facts and causes of the nonconformance in the STACY renewal and modification work, as well as measures to prevent recurrence, remains ongoing, and the company recorded ¥82 million in special investigation expenses. - FY2023-Q1First statedAnnual report
「Following this, the company established an investigation committee, including independent experts, and is currently conducting an investigation to clarify the facts surrounding the nonconformance, identify its causes and make recommendations on measures to prevent recurrence.」
Following the identification of nonconformance in part of the STACY renewal and modification work, the company established an investigation committee including independent experts and is proceeding with fact-finding, cause analysis and recommendations for measures to prevent recurrence.